ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,505.00
0.00%
US Tech 100
19,206.00
1.03%
Dow Jones
40,287.53
0.00%
Brent Oil
81.275
-1.22%
Bitcoin
67,814.39
-0.51%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Genmab AS (GMAB)

  7. Genmab AS (GMAB) News

GMAB

Genmab AS (GMAB)

Genmab AS
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:GMAB
DateTimeSourceHeadlineSymbolCompany
07/17/202410:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GMABGenmab AS
06/28/20242:00AMBusiness WireEpcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular LymphomaNASDAQ:GMABGenmab AS
06/26/20247:08PMBusiness WireEPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)NASDAQ:GMABGenmab AS
06/12/20243:50PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GMABGenmab AS
06/11/20243:30PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GMABGenmab AS
06/10/202412:51PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GMABGenmab AS
06/03/20244:23PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GMABGenmab AS
06/03/20249:00AMBusiness WireInvestigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)NASDAQ:GMABGenmab AS
06/02/20245:30PMBusiness WirePreliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular LymphomaNASDAQ:GMABGenmab AS
06/01/202410:00AMBusiness WireInvestigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)NASDAQ:GMABGenmab AS
05/28/202411:29AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GMABGenmab AS
05/23/20245:00PMBusiness WireGenmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:GMABGenmab AS
05/21/202411:38AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GMABGenmab AS
05/21/202411:18AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GMABGenmab AS
05/21/202411:10AMBusiness WireGenmab Completes Acquisition of ProfoundBioNASDAQ:GMABGenmab AS
05/14/202410:05AMBusiness WireGenmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) CongressNASDAQ:GMABGenmab AS
05/13/202411:29AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GMABGenmab AS
04/29/20246:40PMBusiness WireTIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical CancerNASDAQ:GMABGenmab AS
04/29/20246:40PMBusiness WireFDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical CancerNASDAQ:GMABGenmab AS
04/03/20241:35AMBusiness WireGenmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBioNASDAQ:GMABGenmab AS
03/11/20241:43PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GMABGenmab AS
03/04/20241:50PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GMABGenmab AS
03/04/20241:26PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GMABGenmab AS
03/01/20245:04PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:GMABGenmab AS
02/29/202411:47AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GMABGenmab AS
02/28/202411:06AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GMABGenmab AS
02/27/20244:55PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GMABGenmab AS
02/27/20247:45AMBusiness WireU.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular LymphomaNASDAQ:GMABGenmab AS
02/26/202412:19PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GMABGenmab AS
02/26/202410:40AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GMABGenmab AS
 Showing the most relevant articles for your search:NASDAQ:GMAB

Your Recent History

NASDAQ
CRMT
Americas Car Mart
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved